Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.

Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.
复制标题

DOI:
10.1038/s41598-018-21839-3
复制
发表时间:
2018-02-27
期刊:
影响因子:
4.6
通讯作者:
Li HY
Li HY
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Bharate JB;McConnell N;Naresh G;Zhang L;Lakkaniga NR;Ding L;Shah NP;Frett B;Li HY

文献摘要

参考文献

被引文献

相似文献

FMS样酪氨酸激酶3(FLT 3)是临床验证的急性髓性白血病(AML)靶点。靶向FLT 3的抑制剂已在临床研究中进行了评估,并显示出治疗FLT 3驱动的AML的潜力。一个常见的临床限制是FLT 3选择性,因为认为FLT 3和c-KIT的伴随抑制会导致剂量限制性骨髓抑制。通过合理的设计方法,采用吡啶/嘧啶弹头合成新型FLT 3抑制剂。从研究中鉴定的最有效的化合物是化合物13 a,其对FLT 3激酶的IC 50值为13.9 ± 6.5 nM,与c-KIT相比具有高选择性。作用机制研究表明,13 a是一种II型激酶抑制剂,这也得到了计算机辅助药物发现(CADD)的支持。基于细胞的测定鉴定出13 a对具有临床相关性的多种FLT 3驱动的细胞系是有效的。我们在此报告了基于4,6-二氨基嘧啶的II型FLT 3抑制剂的发现和治疗评价,其可以作为FLT 3选择性支架用于进一步的临床开发。
FMS-like Tyrosine Kinase 3 (FLT3) is a clinically validated target for acute myeloid leukemia (AML). Inhibitors targeting FLT3 have been evaluated in clinical studies and have exhibited potential to treat FLT3-driven AML. A frequent, clinical limitation is FLT3 selectivity, as concomitant inhibition of FLT3 and c-KIT is thought to cause dose-limiting myelosuppression. Through a rational design approach, novel FLT3 inhibitors were synthesized employing a pyridine/pyrimidine warhead. The most potent compound identified from the studies is compound 13a, which exhibited an IC50 value of 13.9 ± 6.5 nM against the FLT3 kinase with high selectivity over c-KIT. Mechanism of action studies suggested that 13a is a Type-II kinase inhibitor, which was also supported through computer aided drug discovery (CADD) efforts. Cell-based assays identified that 13a was potent on a variety of FLT3-driven cell lines with clinical relevance. We report herein the discovery and therapeutic evaluation of 4,6-diamino pyrimidine-based Type-II FLT3 inhibitors, which can serve as a FLT3-selective scaffold for further clinical development.
DOI: 10.1039/c4md00251b
发表时间: 2014-10-01
期刊: MEDCHEMCOMM
影响因子: --
作者:
Frett, Brendan;McConnell, Nick;Li, Hong-yu
通讯作者: Li, Hong-yu
DOI: 10.1016/j.ejmech.2016.05.022
发表时间: 2016-09-14
影响因子: 6.7
作者:
Kim, Hyuntae;Lee, Chulho;Han, Gyoonhee
通讯作者: Han, Gyoonhee
DOI: 10.1002/jcc.21334
发表时间: 2010-01-30
影响因子: 3
作者:
Trott, Oleg;Olson, Arthur J.
通讯作者: Olson, Arthur J.
DOI: 10.1158/1078-0432.ccr-15-1998
发表时间: 2016-08-15
影响因子: 11.5
作者:
Cooper, Todd M.;Cassar, Jeannette;Brown, Patrick A.
通讯作者: Brown, Patrick A.
DOI: 10.1016/j.ejphar.2016.02.048
发表时间: 2016-04-05
影响因子: 5
作者:
Mashkani, Baratali;Tanipour, Mohammad Hossein;Griffith, Renate
通讯作者: Griffith, Renate